Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Drug Costs
  • Insurance Coverage
  • Medicare
  • Quality-Adjusted Life Years

abstract

  • Providing full prescription coverage for AIs to Medicare beneficiaries with hormone receptor-positive early breast cancer would both improve health outcomes and save money from the societal perspective.

publication date

  • July 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.28084

PubMed ID

  • 23775433

Additional Document Info

start page

  • 2494

end page

  • 502

volume

  • 119

number

  • 13